Editas Medicine Surpasses Therapeutic Gene Editing Threshold with 58% Editing Level in Non-Human Primates.

Editas Medicine has surpassed therapeutic gene editing thresholds in new preclinical data, achieving a mean on-target editing level of 58% in non-human primates. The company's use of targeted lipid nanoparticles and in vivo gene editing upregulation strategy sets it apart from other biotech companies. Editas is a clinical-stage biotechnology company developing gene-editing treatments for genetic diseases using CRISPR technology.